Peyronie's Disease News and Research

RSS
Of all penile diseases, Peyronie’s disease represents one with often devastating physical and psychological consequences on affected individuals. Also known as induratio penis plastica, this is an incurable, fibrotic (scarring) disease that results in penile curvature, erectile dysfunction and subsequent coital failure.
Analysis provides new insights into the classification of Peyronie's disease subtypes

Analysis provides new insights into the classification of Peyronie's disease subtypes

Synthetic tissue repairs injuries and restores normal erectile function in pig model

Synthetic tissue repairs injuries and restores normal erectile function in pig model

New device can increase penile length and preserve erectile function in men after prostatectomy

New device can increase penile length and preserve erectile function in men after prostatectomy

Study reports a change in why men seek help for sexual problems

Study reports a change in why men seek help for sexual problems

Why do men stop treatment for erectile dysfunction?

Why do men stop treatment for erectile dysfunction?

Increased risk of cancer among men with a curved penis

Increased risk of cancer among men with a curved penis

BioSpecifics reports net income of $2.7 million for fourth quarter 2015

BioSpecifics reports net income of $2.7 million for fourth quarter 2015

Endo Pharmaceuticals supports efforts to bring first ever treatment guidelines for Peyronie's Disease

Endo Pharmaceuticals supports efforts to bring first ever treatment guidelines for Peyronie's Disease

BioSpecifics Technologies provides corporate update, reports Q4 and FY 2014 financial results

BioSpecifics Technologies provides corporate update, reports Q4 and FY 2014 financial results

Auxilium Pharmaceuticals reports total revenues of $109.6 million for Q3 2014

Auxilium Pharmaceuticals reports total revenues of $109.6 million for Q3 2014

ED more prevalent than previously thought

ED more prevalent than previously thought

BioSpecifics Technologies total revenue for second quarter decreases by 19%

BioSpecifics Technologies total revenue for second quarter decreases by 19%

Auxilium Pharmaceuticals' total revenues decrease 17% to $83 million in Q2 2014

Auxilium Pharmaceuticals' total revenues decrease 17% to $83 million in Q2 2014

Auxilium Pharmaceuticals presents new XIAFLEX clinical trial data at AUA Meeting

Auxilium Pharmaceuticals presents new XIAFLEX clinical trial data at AUA Meeting

Prostate cancer breakthroughs offer new hope for men

Prostate cancer breakthroughs offer new hope for men

Auxilium Pharmaceuticals’ net revenues increase $125.9M to 56%

Auxilium Pharmaceuticals’ net revenues increase $125.9M to 56%

Auxilium Pharmaceuticals reports interim data from XIAFLEX Phase 4 study in patients with DC

Auxilium Pharmaceuticals reports interim data from XIAFLEX Phase 4 study in patients with DC

Auxilium seeks FDA approval for XIAFLEX sBLA to treat multiple Dupuytren's contracture cords concurrently

Auxilium seeks FDA approval for XIAFLEX sBLA to treat multiple Dupuytren's contracture cords concurrently

Auxilium doses first patient in CCH Phase 2b study for treatment frozen shoulder syndrome

Auxilium doses first patient in CCH Phase 2b study for treatment frozen shoulder syndrome

Auxilium Pharmaceuticals' XIAFLEX gets FDA approval for treatment of Peyronie's disease

Auxilium Pharmaceuticals' XIAFLEX gets FDA approval for treatment of Peyronie's disease

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.